Concentrations of Gemifloxacin at the Target Site in Healthy Volunteers after a Single Oral Dose

ABSTRACT Free gemifloxacin concentrations in the interstitial space fluid of skeletal muscle and subcutaneous adipose tissue were measured by means of in vivo microdialysis to characterize the ability of gemifloxacin to penetrate human soft tissues. Twelve healthy volunteers received a single oral dose of 320 mg of gemifloxacin. The mean areas under the concentration-time curves from 0 to 10 h (AUC0-10) were significantly higher for soft tissue than for unbound gemifloxacin in plasma (P < 0.05). The ratios of the mean AUC0-10 for tissue to the AUC0-10 for free gemifloxacin in plasma were 1.7 ± 0.7 (mean ± standard deviation) for skeletal muscle and 2.4 ± 1.0 for adipose tissue. The AUC0-24 ratios for free gemifloxacin in tissues to the MIC at which 90% of frequently isolated bacteria are inhibited were close to or higher than 100 h. Therefore, based on pharmacokinetic and pharmacodynamic calculations, we conclude that gemifloxacin might be a useful therapeutic option for the treatment of soft tissue infections.

[1]  L. Saravolatz,et al.  Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  E. Minar,et al.  Penetration of Moxifloxacin into Healthy and Inflamed Subcutaneous Adipose Tissues in Humans , 2003, Antimicrobial Agents and Chemotherapy.

[3]  J. Walters,et al.  Accumulation of Ciprofloxacin and Minocycline by Cultured Human Gingival Fibroblasts , 2002, Journal of dental research.

[4]  B. Lenfant,et al.  Penetration of telithromycin (HMR 3647), a new ketolide antimicrobial, into inflammatory blister fluid following oral administration. , 2002, The Journal of antimicrobial chemotherapy.

[5]  H. Derendorf,et al.  Microdialysis. A novel tool for clinical studies of anti-infective agents. , 2001, European journal of clinical pharmacology.

[6]  R. Wise,et al.  Pharmacokinetics and tissue penetration of gemifloxacin following a single oral dose. , 2001, The Journal of antimicrobial chemotherapy.

[7]  D. Hooper.  Emerging mechanisms of fluoroquinolone resistance. , 2001, Emerging infectious diseases.

[8]  S. Oliver,et al.  Multiple-Dose Pharmacokinetics and Tolerability of Gemifloxacin Administered Orally to Healthy Volunteers , 2001, Antimicrobial Agents and Chemotherapy.

[9]  Wolzt,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.

[10]  Á. Pascual,et al.  Intracellular Penetration and Activity of Gemifloxacin in Human Polymorphonuclear Leukocytes , 2000, Antimicrobial Agents and Chemotherapy.

[11]  L. Mandell.  Gemifloxacin: survival of the fittest. , 2000, The Journal of antimicrobial chemotherapy.

[12]  P. Ball.  Quinolone generations: natural history or natural selection? , 2000, The Journal of antimicrobial chemotherapy.

[13]  S. Oliver,et al.  Pharmacokinetics and Tolerability of Gemifloxacin (SB-265805) after Administration of Single Oral Doses to Healthy Volunteers , 2000, Antimicrobial Agents and Chemotherapy.

[14]  H. Eichler,et al.  Penetration of Moxifloxacin into Peripheral Compartments in Humans , 1999, Antimicrobial Agents and Chemotherapy.

[15]  H. Eichler,et al.  Distribution and Antimicrobial Activity of Ciprofloxacin in Human Soft Tissues , 1999, Antimicrobial Agents and Chemotherapy.

[16]  Jerome J. Schentag,et al.  Ciprofloxacin concentrations in lung tissue following a single 400 mg intravenous dose. , 1999, The Journal of antimicrobial chemotherapy.

[17]  Á. Pascual,et al.  Uptake and Intracellular Activity of Moxifloxacin in Human Neutrophils and Tissue-Cultured Epithelial Cells , 1999, Antimicrobial Agents and Chemotherapy.

[18]  M. R. Bouw,et al.  Methodological Aspects of the Use of a Calibrator in In Vivo Microdialysis–Further Development of the Retrodialysis Method , 1998, Pharmaceutical Research.

[19]  W. Elmquist,et al.  Application of Microdialysis in Pharmacokinetic Studies , 1997, Pharmaceutical Research.

[20]  H. Pehamberger,et al.  Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans , 1996, Antimicrobial agents and chemotherapy.

[21]  Jerome J. Schentag,et al.  The Importance of Pharmacokinetic/Pharmacodynamic Surrogate Markers to Outcome , 1995, Clinical pharmacokinetics.

[22]  Müller Markus.  Microdialysis , 1992, The Lancet.

[23]  M. Bergeron.  The pharmacokinetics and tissue penetration of the fluoroquinolones. , 1989, Clinical and investigative medicine. Medecine clinique et experimentale.

[24]  Markus Müller,et al.  Microdialysis: current applications in clinical pharmacokinetic studies and its potential role in the future. , 2005, Clinical pharmacokinetics.

[25]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2004, Journal international de bioethique = International journal of bioethics.

[26]  PHARMACOKINETICS AND PHARMACODYNAMICS IN THE DEVELOPMENT OF ANTIBACTERIAL MEDICINAL PRODUCTS , 2000 .

[27]  Tau Fluvalinate,et al.  The European Agency for the Evaluation of Medicinal Products , 1997 .

[28]  D. M. Ryan.  Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans. , 1993, The Journal of antimicrobial chemotherapy.

[29]  Ryan Dm.  Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans , 1993 .